RARA and rheumatoid arthritis: Apart from differences in the pathogenic mechanisms of animal models of RA [17] or in the binding activity of retinoids to RAR subtypes, these experimental data strongly suggest that the anti-arthritic effect of RAR agonists is supported mainly by their ability to reduce the immune response.